Price Is GSK’s Weapon Ahead Of Tanzeum Launch
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline has priced its once-weekly GLP-1 agonist Tanzeum 64% below the high dose of Novo Nordisk’s market-leading, once-daily Victoza – a sign of the uphill commercial battle it faces against an entrenched rival.
You may also be interested in...
FDA approved an easier-to-use pen version of Bydureon for the treatment of type 2 diabetes, but AstraZeneca will need to move quickly and effectively with the launch if it is to establish the brand before other long-acting GLP-1’s enter the market.
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.